Canaan XI L.P. and Affiliates Reduce Stake in Tyra Biosciences to 1.4%

On April 24, 2026, Canaan XI L.P. and associated entities filed an amendment to their Schedule 13G regarding Tyra Biosciences, Inc. (TYRA). The filing indicates a significant reduction in the reporting group's aggregate holdings. Specifically, Canaan 2020+ Co-Investment L.P. - Series 7 and its general partner, Canaan Partners 2020+ Co-Investment, LLC, reported that they no longer beneficially own any shares of the company's common stock as of March 31, 2026. The remaining holdings are held by Canaan XI L.P., which directly owns 750,000 shares, representing approximately 1.4% of the 53,867,115 shares outstanding. Canaan Partners XI LLC, as the general partner of Canaan XI L.P., may also be deemed to beneficially own these shares. This filing marks the third amendment to their original statement and reflects that the reporting persons collectively now own less than 5% of the issuer's common stock. The reporting persons are located in Menlo Park, California, and the shares are held with sole voting and dispositive power by the remaining entities.